|How I Approach MDS Diagnosis and Risk Assessment|
Hetty E. Carraway, MD, MBA, FACP
|Release Date: August 04, 2021|
Expiration Date: August 04, 2022
Join Dr. Carraway as she outlines her strategy for diagnosing myelodysplastic syndromes (MDS) and assessing disease risk. In this newsletter, she reviews differential diagnoses for cytopenias/dysplasia, critical diagnostic tests to include in the MDS diagnostic pathway, MDS subtyping and classification, important prognostic factors and scoring systems, and the impact of somatic mutations on disease course and treatment selection.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grant from Bristol-Myers Squibb and Taiho Oncology, Inc.
|Begin, Earn CreditView Only, No Credit|